Evaluating the association between type of prescription drug plan and asthma patients' use of controller medications

Journal of Pharmaceutical Health Services Research

Volumn 3, Issue 2, 2012, Pages 65-69

  Vaidya, Varun ^a   Peeters, Michael J ^a   Partha, Gautam ^a   Potnis, Priyanka ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Asthma; Controller drug use; Medicare; Prescription drug benefit

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTHMA; CROSS-SECTIONAL STUDY; DISEASE CONTROL; DRUG UTILIZATION; ETHNICITY; FEMALE; GENDER; HEALTH INSURANCE; HEALTH STATUS; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRESCRIPTION DRUG PLAN; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RACE; RETROSPECTIVE STUDY; SELF REPORT; UNITED STATES;

EID: 84860673583     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2012.00082.x     Document Type: Article

References (32)

1. Rak JM etal. Male microchimerism and HLA compatibility in French women with sclerodema: a different profile in limited and diffuse subset. Rheumatol (Oxf) 2009; 48: 363-366.
2. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma 2009; 46: 73-80.
3. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120(5 Suppl.): S94-S138.
4. Bahadori K etal. Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9: 24.
5. Masoli M etal. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478.
6. Sullivan PW etal. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol 2011; 127: 363-369; e363.
7. Franco R etal. The economic impact of severe asthma to low-income families. Allergy 2009; 64: 478-483.
8. Finkelstein JA etal. Underuse of controller medications among Medicaid-insured children with asthma. Arch Pediatr Adolesc Med 2002; 156: 562-567.
9. Williams LK etal. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128: 1185-1191; e1182.
10. Korhonen K etal. Use of inhaled corticosteroids decreases hospital admissions for asthma in young children. World J Pediatr 2009; 5: 177-181.
11. Rabe KF etal. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.
12. Walders N etal. Patterns of quick-relief and long-term controller medication use in pediatric asthma. J Pediatr 2005; 146: 177-182.
13. Kozyrskyj AL etal. Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ 2001; 165: 897-902.
14. Tseng CW etal. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 2004; 292: 952-960.
15. Brixner DI etal. Effects of benefit design change across 5 disease states. Am J Manag Care 2007; 13(6 Pt 2): 370-376.
16. Lundy J. Prescription Drug Trends. Menlo Park, CA: Kaiser Family Foundation, 2010.
17. Gibson TB etal. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005; 11: 730-740.
18. Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Med Care Res Rev 2004; 61: 415-452.
19. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001; 39: 1293-1304.
20. Anis AH etal. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. CMAJ 2001; 164: 625-631.
21. Wagner TH etal. Prescription drug co-payments and cost-related medication underuse. Health Econ Policy Law 2008; 3(Pt 1): 51-67.
22. Ungar WJ etal. Effect of cost-sharing on use of asthma medication in children. Arch Pediatr Adolesc Med 2008; 162: 104-110.
23. Vaidya V etal. Demographic disparities in patient-reported use of inhaled corticosteroids among patients with persistent asthma. J Asthma Allergy 2010; 3: 101-106.
24. Rice T etal. The impact of private and public health insurance on medication use for adults with chronic diseases. Med Care Res Rev 2005; 62: 231-249.
25. Vila D etal. Disparities in asthma medication dispensing patterns: the case of pediatric asthma in Puerto Rico. J Asthma 2010; 47: 1136-1141.
26. Bontá DM. Asthma Management/Pharmaceutical Utilization 2002 Report. Division M-CMC, ed. California Department of Health Services; 2003.
27. Centers for Medicare and Medicaid Services. Your Guide to Medicare Prescription Drug Coverage. 2012. (accessed 9 March 2012).
28. Farley JF, Dusetzina SB. Medicaid prescription drug utilization and expenditures following Part D. J Health Care Poor Underserved 2010; 21: 715-728.
29. Kaiser Family Foundation. Medicaid: a primer key information on the nation's health program for low-income people. Report no. 7334-03. Menlo Park, CA: Kaiser Family Foundation, 2009.
30. Anon. Impact of copays on vulnerable populations. Am J Manag Care 2006; 12(13 Suppl.): S359-S363.
31. Kaiser Family Foundation. Prescription Drug Trends. Menlo Park, CA: Kaiser Family Foundation, 2007.
32. Schafheutle EI. The impact of prescription charges on asthma patients is uneven and unpredictable: evidence from qualitative interviews. Prim Care Respir J 2009; 18: 266-272.